NEUROCRINE BIOSCIENCES INC
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Cash flows from operating activities: | ||
| Net income | $238.2 | $102.0 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Stock-based compensation expense | 129.1 | 156.2 |
| Charges associated with convertible senior notes | 138.4 | — |
| Impairment charges associated with leased properties | 14.0 | — |
| Depreciation | 17.3 | 12.9 |
| Accretion of discount on available-for-sale debt securities, net | (20.6) | (12.0) |
| Amortization of intangible assets | 2.7 | 2.7 |
| Changes in fair values of equity investments | 35.2 | 0.6 |
| Deferred income taxes | (91.8) | (77.3) |
| Other | 3.9 | (0.6) |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (41.8) | (67.9) |
| Inventory | (7.5) | 6.3 |
| Accounts payable and accrued liabilities | (38.7) | 147.3 |
| Other assets and liabilities, net | (25.5) | (3.8) |
| Cash flows from operating activities | 352.9 | 266.4 |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (744.3) | (892.7) |
| Sales and maturities of available-for-sale debt securities | 716.7 | 681.6 |
| Purchases of equity investments | — | (31.3) |
| Capital expenditures | (30.9) | (22.9) |
| Cash flows from investing activities | (58.5) | (265.3) |
| Cash flows from financing activities: | ||
| Issuances of common stock under benefit plans | 112.1 | 29.9 |
| Payments to settle convertible senior notes | (308.8) | — |
| Cash flows from financing activities | (196.7) | 29.9 |
| Effect of exchange rate changes on cash and cash equivalents | 0.3 | — |
| Change in cash, cash equivalents and restricted cash | 98.0 | 31.0 |
| Cash, cash equivalents and restricted cash at beginning of period | 259.1 | 270.7 |
| Cash, cash equivalents and restricted cash at end of period | $357.1 | $301.7 |
| Supplemental disclosures: | ||
| Accrued capital expenditures | $0.8 | $0.9 |
| Right-of-use assets acquired through operating leases | $9.0 | $1.8 |
| Cash paid for interest | $1.6 | $1.9 |
| Cash paid for income taxes | $144.5 | $5.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.